The new MFN Life Sciences AI Challenge is a workshop-based accelerator program that supports startups using AI to advance life sciences R&D solutions.
Five Massachusetts-based teams have been selected to participate over the next twelve weeks to advance their companies. This challenge was developed based on interviews with leaders across the pharma, biotech, and consulting industries. Large life science companies are looking for startups that deliver measurable business value through better decisions, improved efficiency, and workforce transformation.
A $35,000 innovation grant will be awarded to the team that presents the most scalable business model at the final pitch event in September – stay tuned for more details!
Meet the Finalists!
- Akttyva Therapeutics: Led by founder and CEO Katya Tsaioun-Hélin
Akttyva is an early-stage drug discovery platform that combines AI andphysics to identify prospective drug compounds most likely to succeed in validation studies.
- Celvion Therapeutics: Led by founder and CEO Mi Yang
Celvion’s platform EMphora forecasts synergistic protein target combinations to address gaps in cancer therapy.
- ScriptBio: Led by founder and CEO Patrick Ovando Roche
ScriptBio’s multi-agent technology identifies disease-causative genes to be targeted by new therapies.
- Polyforge: Led by founder and CEO Jared Broberg
Polyforge is building an AI-integrated Operations Management System to optimize processes and operations in drug manufacturing.
- SequestBio: Led by founder and CEO Ashkan Novin
SequestBio is building an AI and quantum-assisted platform to provide intelligence for pharmaceutical discoveryR&D and clinical validation.
The MFN Life Sciences AI Challenge is produced in collaboration with the Massachusetts Business Roundtable (MBR) and sponsored by the Massachusetts Life Sciences Center (MLSC).
